Agenovir Lands $10,600,000 Series A Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=a467dbdc-96dc-4941-ba22-7efcaa4798bd - Date
5/18/2016 - Company Name
Agenovir - Mailing Address
329 Oyster Point Blvd. 3rd Floor South San Francisco, CA 94080 USA - Company Description
Agenovir is a leader in the research and development of a novel class of human therapeutics to address diseases associated with or caused by latent or persistent viral reservoirs. The individuals affected by these diseases number in the millions, and treatment options are extremely limited or non-existent. - Website
http://www.agenovir.com - Transaction Type
Venture Equity - Transaction Amount
$10,600,000 - Transaction Round
Series A - Proceeds Purposes
With this financing led by top tier venture, corporate and individual investors, we expect to build an exceptional leadership team and accelerate our research and development programs to treat diseases associated or caused by latent or persistent viral reservoirs. - M&A Terms
- Venture Investor
Data Collective - Venture Investor
Celgene - Venture Investor
Lightspeed Venture Partners - Venture Investor
Undisclosed
